Le Gallo Matthieu, Rudd Meghan L, Urick Mary Ellen, Hansen Nancy F, Merino Maria J, Mutch David G, Goodfellow Paul J, Mullikin James C, Bell Daphne W
Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland.
National Institutes of Health Intramural Sequencing Center, National Institutes of Health, Rockville, Maryland.
Cancer. 2018 Jan 1;124(1):65-73. doi: 10.1002/cncr.30971. Epub 2017 Sep 21.
Uterine carcinosarcomas (UCSs) are a rare but clinically aggressive form of cancer. They are biphasic tumors consisting of both epithelial and sarcomatous components. The majority of uterine carcinosarcomas are clonal, with the carcinomatous cells undergoing metaplasia to give rise to the sarcomatous component. The objective of the current study was to identify novel somatically mutated genes in UCSs.
We whole exome sequenced paired tumor and nontumor DNAs from 14 UCSs and orthogonally validated 464 somatic variants using Sanger sequencing. Fifteen genes that were somatically mutated in at least 2 tumor exomes were Sanger sequenced in another 39 primary UCSs.
Overall, among 53 UCSs in the current study, the most frequently mutated of these 15 genes were tumor protein p53 (TP53) (75.5%), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) (34.0%), protein phosphatase 2, regulatory subunit A, alpha (PPP2R1A) (18.9%), F-box and WD repeat domain containing 7 (FBXW7) (18.9%), chromodomain helicase DNA binding protein 4 (CHD4) (17.0%), and forkhead box A2 (FOXA2) (15.1%). FOXA2 has not previously been implicated in UCSs and was predominated by frameshift and nonsense mutations. One UCS with a FOXA2 frameshift mutation expressed truncated FOXA2 protein by immunoblotting. Sequencing of FOXA2 in 160 primary endometrial carcinomas revealed somatic mutations in 5.7% of serous, 22.7% of clear cell, 9% of endometrioid, and 11.1% of mixed endometrial carcinomas, the majority of which were frameshift mutations.
Collectively, the findings of the current study provide compelling genetic evidence that FOXA2 is a pathogenic driver gene in the etiology of primary uterine cancers, including UCSs. Cancer 2018;124:65-73. © 2017 American Cancer Society.
子宫癌肉瘤(UCS)是一种罕见但临床侵袭性强的癌症形式。它们是由上皮和肉瘤成分组成的双相肿瘤。大多数子宫癌肉瘤是克隆性的,癌细胞经历化生以产生肉瘤成分。本研究的目的是鉴定UCS中新型的体细胞突变基因。
我们对来自14例UCS的配对肿瘤和非肿瘤DNA进行了全外显子组测序,并使用桑格测序对464个体细胞变异进行了正交验证。在另外39例原发性UCS中,对至少在2个肿瘤外显子组中发生体细胞突变的15个基因进行了桑格测序。
总体而言,在本研究的53例UCS中,这15个基因中最常发生突变的是肿瘤蛋白p53(TP53)(75.5%)、磷脂酰肌醇-4,5-二磷酸3-激酶催化亚基α(PIK3CA)(34.0%)、蛋白磷酸酶2调节亚基Aα(PPP2R1A)(18.9%)、含F盒和WD重复结构域7(FBXW7)(18.9%)、染色质结构域解旋酶DNA结合蛋白4(CHD4)(17.0%)和叉头框A2(FOXA2)(15.1%)。FOXA2此前未被认为与UCS有关,且主要为移码突变和无义突变。1例具有FOXA2移码突变的UCS通过免疫印迹法表达截短的FOXA2蛋白。对160例原发性子宫内膜癌的FOXA2测序显示,浆液性癌中5.7%、透明细胞癌中22.7%、子宫内膜样癌中9%以及混合性子宫内膜癌中11.1%存在体细胞突变,其中大多数为移码突变。
总体而言,本研究结果提供了令人信服的遗传学证据,表明FOXA2是包括UCS在内的原发性子宫癌病因中的致病驱动基因。《癌症》2018年;124:65 - 73。©2017美国癌症协会。